Jean P. Bassand

Aug 18, 2023 | onlinelibrary.wiley.com | Alan John Camm |Saverio Virdone |Daniel E. Singer |Jean P. Bassand

1 INTRODUCTION Patients with atrial fibrillation (AF) have five times higher risk of stroke and two times higher risk of all-cause mortality compared to the age-matched general population.1 Standard of care for mitigating stroke risk is prophylactic oral anticoagulant (OAC) therapy using vitamin K antagonists (VKAs) or non-VKA oral anticoagulants (NOACs). However, the benefit of these drugs must be balanced against an increased risk of bleeding.